Dexmedetomidine is safe and reduces the additional dose of midazolam for sedation during endoscopic retrograde cholangiopancreatography in very elderly patients

Osamu Inatomi1*, Takayuki Imai1, Takehide Fujimoto1, Kenichiro Takahashi1, Yoshihiro Yokota1, Noriaki Yamashita1, Hiroshi Hasegawa1, Atsushi Nishida1, Shigeki Bamba2, Mitsushige Sugimoto3 and Akira Andoh1

Abstract

Background: Endoscopic retrograde cholangiopancreatography (ERCP) often requires deep sedation. Dexmedetomidine, a highly selective α2-adrenoceptor agonist with sedative activity and minimal effects on respiration, has recently been widely used among patients in the intensive care unit. However, its use in endoscopic procedures in very elderly patients is unclear. In this study, we retrospectively investigated the safety and efficacy of dexmedetomidine sedation during ERCP.

Methods: The study included 62 very elderly patients (aged over 80 years) who underwent ERCP from January 2014, with sedation involving dexmedetomidine (i.v. infusion at 3.0 μg/kg/h over 10 min followed by continuous infusion at 0.4 μg/kg/h) along with midazolam. For comparison, the study included 78 patients who underwent ERCP before January 2014, with midazolam alone. We considered additional administration of midazolam as needed to maintain a sedation level of 3–4, according to the Ramsay sedation scale. The outcome measures were amount of midazolam, adverse events associated with sedation, and hemodynamics.

Results: The incidence of decreased SpO2 and median dose of additional midazolam were significantly lower in the dexmedetomidine group than in the conventional group. The minimum systolic blood pressure and minimum heart rate during and after examination was significantly lower in the dexmedetomidine group than in the conventional group. However, serious acute heart failure or arrhythmia was not noted.

Conclusions: Dexmedetomidine can decrease the incidence of respiratory complications and the total dose of other sedative agents. It can be used as an alternative to conventional methods with midazolam for adequate sedation during ERCP in very elderly patients.

Keywords: Midazolam, Dexmedetomidine, Cholangiopancreatography, Endoscopic
Background
Sedation in gastrointestinal endoscopy helps to not only alleviate the discomfort experienced by patients but also to improve the performance of the operator [1–3]. However, sedation can cause serious complications, such as respiratory depression and heart failure. Therefore, it is necessary to consider the safety (frequency of complications) as well as the sedative effects when selecting sedatives. In particular, very elderly patients undergoing endoscopic procedures are generally prone to sedation complications [4, 5].

Currently, benzodiazepines, such as midazolam and propofol, are widely used in endoscopic treatment, and they show an increased dose-dependent frequency of respiratory depression [6–9]. Endoscopic retrograde cholangiopancreatography (ERCP) is more invasive than other endoscopic procedures, and it often requires a comparatively deep sedation [10, 11]. It is known that the combined use of sedatives having different mechanisms of action results in synergistic sedative effects [12, 13]. Thus, the dose of each drug can be decreased, and it is possible to prevent the onset of negative incidents.

Dexmedetomidine (DEX) has low analgesic and sedative effects with low respiratory depression, and its usefulness for sedation in intensive care and local anesthesia treatment has been reported in recent years [14–16]. As it is associated with low respiratory suppression, its usefulness has been reported for sedation in endoscopic treatment [17–19]; however, its effectiveness and safety are unclear in very elderly patients undergoing ERCP. In this study, we retrospectively analyzed the influence of the combined use of DEX and midazolam for sedation during ERCP in very elderly patients.

Methods
Patients
Between January 2014 and June 2016, 62 consecutive patients aged over 80 years received DEX for sedation during ERCP at our hospital, and they were included in the DEX group. Between April 2012 and December 2013, 78 consecutive patients received midazolam alone, and they were included in the conventional group. The patients that the baseline percutaneous arterial blood oxygen saturation (SpO2) was less than 90, the systolic blood pressure was 60 mmHg or less, or the heart rate was 40 beats/min or less were excluded from analysis. All patients provided informed written consent prior to undergoing ERCP. The study was conducted in agreement with the Declaration of Helsinki and received approval from the ethics committee of Shiga University of Medical Sciences and conformed to its guidelines.

Sedation procedure
Endoscopic examination was performed by three expert gastrointestinal endoscopists. In all patients, the sedative was administered by a sedative physician (non-anesthesiologist) who was familiar with the use of sedatives. The JF-260 V system (Olympus Medical Systems, Tokyo, Japan) was used. Oxygen (2 L/min) was administered at the start of the examination. During the examination, blood pressure, heart rate, and SpO2 were continuously monitored, and an electrocardiogram was continuously obtained.

In the DEX group, the initial dose of DEX (Presedex, Pfizer, Tokyo, Japan) was set at 3 μg/kg/h, and after loading for 10 min, the dose was reduced to 0.4 μg/kg/h with the range described in previous reports [18, 20]. Continuous infusion was carried out with the maintenance dose until the end of the examination. Additionally, 2.5 mg of midazolam (Astellas Pharma, Tokyo, Japan) was intravenously injected at the start of the examination. A single intravenous injection of 2 mg of midazolam was repeated to maintain the sedation level at 3–4, according to the Ramsay sedation scale (RSS) [21].

In the conventional group, 2.5 mg of midazolam was intravenously injected at the start of the examination. A single intravenous injection of 2 mg of midazolam was repeated to maintain the sedation level at 4 according to the RSS, as in the DEX group (Fig. 1).

In both groups, catecholamine was administered when the systolic blood pressure was 60 mmHg or less, and atropine was administered when the heart rate was 40 beats/min or less for more than 10 s.

Endpoints and evaluation
The main endpoint of effectiveness was the amount of midazolam. The secondary endpoint was the frequency of respiratory depression associated with sedation, the frequency of occurrence of acute heart failure and brady-arrhythmia, and time-dependent changes in blood pressure and heart rate and the frequency of administration of catecholamine and atropine. Blood pressure and heart rate were continuously measured from the start of sedation until the end of the examination, and the pre-examination values (at the time of entering the examination room), the lowest values during examination (minimum blood pressure/minimum heart rate), and the post-examination values (10 min after examination) were evaluated. Respiratory depression was defined as SpO2 < 90 during the examination. Procedure time was defined as the time from endoscope insertion to end of the examination.

Statistical analysis
Measurement results are shown as median and quartile range for variables with non-normal distribution (amount
of drug used) and mean ± standard deviation for variables with normal distribution (blood pressure, heart rate, and oxygen dose). Drug use was analyzed using the Mann–Whitney U test; background factors and complication frequency were analyzed using the chi-square test, and circulatory dynamics over time were analyzed using repeated measures analysis of variance (ANOVA). A P-value < 0.05 was considered to indicate a significant difference.

Results

Patient background
There was no significant difference between the DEX group and conventional group with regard to age, sex, body mass index (BMI), medical history, NYHA classification, reason for examination, content of enforcement treatment, and mean examination time (Table 1).

Comparison of total dose of midazolam
The median dose of midazolam was significantly lower in the DEX group (10.0 mg) than in the conventional group (18.0 mg) (p < 0.001) (Fig. 2).

The frequency of respiratory depression
The frequency of respiratory depression was significantly lower in the DEX group (0%) than in the conventional group (6.9%) (p = 0.04). In the two patients of the conventional group we could not continue the examination due to respiratory insufficiency.

Sedation-related complications
Issues related to circulatory dynamics, including heart failure, sick sinus syndrome, and advanced atrioventricular block, were not observed in both groups. Atropine

### Table 1 Patient background

|                | DEX group (n = 62) | Conventional group (n = 87) | P-value |
|----------------|-------------------|-----------------------------|---------|
| Age            | 85.2 (81–94)      | 85.4 (80–99)                | 0.30    |
| Sex (M/F)      | 39/23             | 30/57                       | 0.13    |
| BMI (kg/m²)    | 21.1              | 19.7                        | 0.08    |
| Comorbidity    |                   |                              |         |
| Ischemic heart disease | 15   | 23                          | 0.85    |
| Chronic heart failure      | 28  | 34                          | 0.50    |
| Arrhythmia      | 22                | 23                          | 0.28    |
| NYHA classification |      |                              |         |
| No cardiovascular disease | 34  | 53                          | 0.50    |
| Class I        | 25                | 32                          | 0.73    |
| ≥ Class II     | 3                 | 2                           | 0.65    |
| Diagnosis      |                   |                              |         |
| Biliary stone  | 40                | 44                          | 0.10    |
| Biliary cancer | 20                | 38                          | 0.18    |
| Others         | 2                 | 5                           | 1.0     |
| Procedure      |                   |                              |         |
| EST            | 21                | 23                          | 0.37    |
| EPBD           | 12                | 8                           | 0.43    |
| ENBD           | 10                | 14                          | 1.0     |
| Biliary stent  | 24                | 42                          | 0.31    |
| Procedure time (min, mean ± SD) | 45.0 ± 30.1 | 48.5 ± 31.2 | 0.94 |

EST endoscopic sphincterotomy, EPBD endoscopic papillary balloon dilatation, ENBD endoscopic nasobiliary drainage
Inatomi et al. BMC Gastroenterology (2018) 18:166

Fig. 2 Comparison of total dose of midazolam in DEX (combined dexmedetomidine and midazolam) and conventional group (midazolam alone). *p < 0.01

Fig. 3 The mean lowest systolic blood pressure during the examination. The decreases were significant in both the groups when compared with the values before the examination. In the conventional group, the post-test blood pressure improved, whereas in the DEX group, the decrease in blood pressure was significantly prolonged even after the examination. * < 0.01

Fig. 4 The mean lowest heart rate during the examination. In DEX group, the value was significantly lower than that before the examination. In the conventional group, the value was similar to that before the examination. In addition, in the DEX group, the decrease in heart rate was significantly prolonged even after the examination (mean 67.2 beats/min), whereas in the conventional group, the heart rate after the examination improved (mean 79.9 beats/min) (Fig. 4).

Discussion

In this study, the combined use of DEX was found to significantly reduce the amount of midazolam, resulting in a decrease in the frequency of respiratory suppression events in very elderly patients undergoing ERCP. Although DEX tended to lower the minimum blood pressure and heart rate during examination, complications related to serious circulatory dynamics did not occur.
DEX acts on the locus ceruleus located in the pons, and it activates the α2-receptor present in noradrenaline neurons and induces sedation by suppressing upper neuron activity through negative feedback. In contrast to many other sedatives, it is characterized by limited affinity for gamma-aminobutyric acid (GABA) receptors, and therefore, there is almost no respiratory depression [21].

Although sedation by DEX has been reported for its usefulness in other endoscopic procedures, such as upper and lower endoscopy for screening purposes and endoscopic submucosal dissection (ESD), its effectiveness in ERCP is controversial. Muller et al. and Mazanikov et al. reported that it was not sufficiently effective when used alone [22, 23], while Lee et al. reported that it was not sufficiently effective when used alone [22, 23], while Lee et al. reported that it was not sufficiently effective when used alone [22, 23], while Lee et al. reported that it was not sufficiently effective when used alone [22, 23], while Lee et al. reported that it was not sufficiently effective when used alone [22, 23], while Lee et al. reported that it was not sufficiently effective when used alone [22, 23]

Inatomi et al. BMC Gastroenterology (2018) 18:166

In this study, the minimum systolic blood pressure and heart rate during and after the examination decreased significantly with DEX when compared to that with conventional sedation. Although catecholamine and atropine were used in some patients, we judged it was clinically acceptable as blood pressure and heart rate recovered promptly after discontinuing the administration of DEX, and there was no serious circulatory problem such as acute heart failure or severe atrioventricular block failure during the recovery period in the all patients. However, comparative study with other sedative such as propofol may be needed for more safe sedation in circulation dynamics.

In addition, DEX may not be suitable for ERCP in the case of emergency as protocol with DEX include loading time for about 10 min before the start of ERCP procedure. Improvement of the protocol with shorter loading time might solve this problem.

The present study has some limitations. This was a retrospective study performed at a single center, and it did not involve blinding. However, information bias was minimal as we used DEX in consecutive cases and adjusted the dose by setting certain criteria for reducing/adding sedatives. A prospective, randomized study is needed to clarify the appropriate sedative protocol for ERCP in very elderly patients.

**Conclusion**

Dexmedetomidine can decrease the incidence of respiratory complications and the total dose of other sedative agents. Combined protocol using sedative agents with different pharmacokinetics may minimize the side effects of each. Dexmedetomidine can be used as an alternative to conventional methods with midazolam for adequate sedation during ERCP in very elderly patients.

**Abbreviations**

ANOVA: Analysis of variance; DEX: Dexmedetomidine; ERCP: Endoscopic retrograde cholangiopancreatography; ESD: Endoscopic submucosal dissection; GABA: Gamma-aminobutyric acid; RSS: Ramsay sedation scale; SpO2: Percutaneous arterial blood oxygen saturation

**Acknowledgements**

There are no further sources of funding for the study, authors, or preparation of the manuscript.

**Funding**

All authors disclosed no financial relationships relevant to this study.

**Availability of data and materials**

The datasets used during the current study available from the corresponding author on reasonable request.

**Authors’ contributions**

OI was involved in analyzing the results and writing the manuscript. TI, YY, and NY participated in the design of the study and performed the statistical analysis. TF, KT and HH helped procedure for ERCP. SB, MS and AA conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All patients provided informed written consent prior to undergoing ERCP. The study was conducted in agreement with the Declaration of Helsinki and received approval from the ethics committee of Shiga University of Medical Sciences and conform to its guidelines.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Division of Gastroenterology, Department of Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan. 2 Division of Clinical Nutrition, Department of Medicine, Shiga University of Medical Science, Otsu, Japan. 3 Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Otsu, Japan.

Received: 4 May 2018 Accepted: 24 October 2018 Published online: 06 November 2018

References
1. Cohen LB, Wessler JS, Gaetano JN, Benson AA, Miller KM, Durkalski V, et al. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol. 2006;101:967–74.
2. Cohen LB, DeLegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, et al. ACG Institute review of endoscopic sedation. Gastroenterology. 2007;133:675–701.
3. McCuald KR, Laine L. A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures. Gastrointest Endosc. 2008;68:910–23.
4. Travis AC, Pievsky D, Saltzman JR. Endoscopy in the elderly. Am J Gastroenterol. 2012;107:1495–501.
5. Clarke GA, Jacobson BC, Hammett RJ, Can-Locke DL. The indications, utilization and safety of gastrointestinal endoscopy in an extremely elderly patient cohort. Endoscopy. 2001;33:580–4.
6. Ross WA. Premedication for upper gastrointestinal endoscopy. Gastrointest Endosc. 1989;35:120–6.
7. Freeman ML. Sedation and monitoring for gastrointestinal endoscopy. Gastrointest Endosc Clin N Am. 1994;4:475–99.
8. Fageol DO, Baron TH, Goldstein JL, Hirota WK, Jacobson BC, Johanson JF, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc. 2002;56:613–7.
9. Perel A. Non-anaesthesiologists should not be allowed to administer propofol for procedural sedation: a consensus statement of 21 European National Societies of Anaesthesia. Eur J Anaesthesiol. 2011;28:580–4.
10. Riphaus A, Stegou N, Wehrmann T. Sedation with propofol for routine ERCP in high-risk octogenarians: a randomized, controlled study. Am J Gastroenterol. 2005;100:1957–63.
11. Patel S, Vargo JJ, Khandwala F, Lopez R, Torti P, Dumot JA, et al. Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam. Am J Gastroenterol. 2005;100:2689–95.
12. Salonen M, Onalvi ES, Maze M. Dexmedetomidine synergism with midazolam in the elevated plus-maze test in rats. Psychopharmacology. 1992;108:229–34.
13. Bergese SD, Patrick Bender S, McSweeney TD, Fernandez S, Dzwonczyk R, Sage K. A comparative study of dexmedetomidine with midazolam and midazolam alone for sedation during elective awake fiberoptic intubation. J Clin Anesth. 2010;22:95–40.
14. Bradley C. Dexmedetomidine—a novel sedative for postoperative sedation. Intensive Crit Care Nurs. 2000;16:328–9.
15. Hall JE, Uhrich TD, Bany JF, Aasen SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90:699–705.
16. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301:489–99.
17. Demiraran Y, Korkut E, Turner A, Yorulmaz I, Kokoran B, Sezen G, et al. The comparison of dexmedetomidine and midazolam used for sedation of patients during upper endoscopy: a prospective, randomized study. Can J Gastroenterol. 2007;21:25–9.
18. Takimoto K, Ueda T, Shimamoto F, Kojima Y, Fujinaga Y, Kashiwa A, et al. Sedation with dexmedetomidine hydrochloride during endoscopic submucosal dissection of gastric cancer. Dig Endosc. 2011;23:176–81.
19. Nishizawa T, Suzuki H, Sagara S, Kanai T, Yahagi N. Dexmedetomidine versus midazolam for gastrointestinal endoscopy: A meta-analysis. Dig Endosc. 2015;27:18–51.
20. Nonaka T, Inamori M, Miyashita T, Harada S, Inoh Y, Kanoshima K, et al. Feasibility of deep sedation with a combination of propofol and dexmedetomidine hydrochloride for esophageal endoscopic submucosal dissection. Dig Endosc. 2015;28:145–51.
21. Hayashi Y, Sumikawa K, Maze M, Yamatodani A, Kamibayashi T, Kuro M, et al. Dexmedetomidine prevents epinephrine-induced arrhythmias through stimulation of central a2a adrenoceptors in halothane-anesthetized dogs. Anesthesiology. 1991;75:133–7.
22. Muller S, Borowics SM, Fortis EAF, Stefani LC, Soares G, Magulnick I, et al. Clinical efficacy of dexmedetomidine alone is less than propofol for conscious sedation during ERCP. Gastrointest Endosc. 2008;67:651–9.
23. Mazarakis M, Udd M, Kylin-Ljau L, Mustonen H, Lindström D, Halttunen J, et al. Dexmedetomidine impairs success of patient-controlled sedation in alcoholics during ERCP. Gastrointest Endosc. 2008;67:651–9.
24. Lee BS, Ryu J, Lee SH, Lee MG, Jang SE, Hwang J-H, et al. Midazolam with meperidine and dexmedetomidine vs. midazolam with meperidine for sedation during ERCP: prospective, randomized, double-blinded trial. Endoscopy. 2014;46:291–8.
25. Kim EH, Park JC, Shin SK, Lee YC, Lee SK. Effect of the midazolam added with propofol-based sedation in esophagogastroduodenoscopy: a randomized trial. J Gastroenterol Hepatol. 2018;33:894–9.
26. Salminen P, Grönroos J. Anaesthesiologist assistance in endoscopic retrograde cholangiopancreatography procedures in the elderly: is it worthwhile? J Laparoendosc Adv Surg Tech A. 2011;21:517–9.
27. Qureshi WA, Zuckerman MJ, Adler DG, Davila RE, Egan JV, Gan SI, et al. ASGE guideline: modifications in endoscopic practice for the elderly. Gastrointest Endosc. 2006;63:566–9.
28. Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth. 2001;87:684–90.
29. Herr DL, Sum-Ping STJ, England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth. 2003;17:576–84.